Abstract 435P
Background
Young adults form an essential component of the country's active population and significantly impact the health-care strategy of the nation. Cancer patterns and biology in this age group differ from those in pediatric and older adults. Cancer in this age group may be due to a combination of environmental and congenital factors or neither of them. It may result from spontaneous mutations to a malignant phenotype unrelated to environmental or inherited factors. The literature is relatively scarce in the context of Indian patients diagnosed with cancer in a younger age group. This study aims at describing the disease profile of these patients in the Indian population.
Methods
The current study is a retrospective analysis of young adult patients of age between 18-39 years registered and treated from January 2018 to September 2021 in the department of Radiation Oncology. The following demographic profile and parameters were assessed: Age, gender, ECOG performance status (PS), addiction and family history, site of primary malignancies, and stage of the disease.
Results
A total of 8588 patients were registered during the study period. Of them, 850 patients ( 10%) were between the ages of 18-39. Maximum (73%) of the patient belonged to the 30-39years age group. Male to female ratios were almost equal. Young male patients were 51.6%, and females were 48.4%. Patients visiting from local region & state were 45.4% whereas from nearby states were 54.5%. 52% of patients presented with good performance score (PS ≤2). Positive family history of malignancy was found in only 3.5%, whereas 24% of the patients gave an addiction history of smoking/tobacco chewing or alcohol. The most commonly observed malignancies were with the head and neck (28%), followed by the breast (22%). Head and neck cancer mainly were observed in males (23.8%), whereas females (20.8%) had higher breast cancer. Table: 435P
Overall stage groupIIIIIIV | 5%14%32%48% |
SitesHead & neckBreastGastrointestinalGenitourinaryCentral nervous systemSarcomaHepatobiliaryLungSkin/others | 28.5%23%9.8%9.6%9.6%8.2%4.8%2.3%2.7% |
Conclusions
Cancer among young adult patients forms a primary concern, especially in developing countries. The incidence of advanced and metastatic disease in this group is alarming. Reinforcement of screening programs in this age group should be a priority.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NA.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06